Drug intelligence / Profile preview

lactobacillus bulgaricus 6c3

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus bulgaricus 6c3 is a specific probiotic bacterial strain identified for its ability to reduce serum levels of indoxyl sulfate (IS), a uremic toxin associated with the progression of chronic kidney disease (CKD) and cardiovascular complications. In research settings, it has been formulated as a synbiotic by combining the lyophilized bacteria (at a concentration of 10^6 CFU/g) with the prebiotics inulin and fructooligosaccharides (FOS). The strain was selected based on its superior probiotic functionality and safety profile, showing 99.7% similarity to Lactobacillus bulgaricus via 16S rRNA sequencing. In preclinical rat models of CKD, administration of this synbiotic significantly attenuated the increase of indoxyl sulfate and reduced renal fibrosis, although it did not show protective effects against cardiac fibrosis. It is currently an academic research compound rather than a commercially developed pharmaceutical.

Other names: Lactobacillus bulgaricus 6c3

Targets

IS (Indoxyl sulfate)

Beyond the preview

Go deeper on lactobacillus bulgaricus 6c3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus bulgaricus 6c3.

Explore the full profile